Compare $NRIX vs $SLS | Chartloom

Compare

$NRIX vs $SLS

Nurix Therapeutics Inc · Sellas Life Sciences Group Inc

NRIX

Nurix Therapeutics Inc

SLS

Sellas Life Sciences Group Inc

Compare $NRIX vs $SLS

Comparing Nurix Therapeutics Inc and Sellas Life Sciences Group Inc

NRIXNurix Therapeutics Inc

SLSSellas Life Sciences Group Inc

NRIXNurix Therapeutics Inc

Market cap

$2.32B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

24.84x

Rev growth (TTM)

-58.4%

YTD performance

23.8%

52W performance

123.9%

FCF yield

-13.1%

SLSSellas Life Sciences Group Inc

Market cap

$2.29B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

167.8%

52W performance

503.6%

FCF yield

-1.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NRIX

SLS

Detailed metrics comparison

NRIX

Nurix Therapeutics Inc

SLS

Sellas Life Sciences Group Inc

Market Cap

NRIX$2.32B

SLS$2.29B

Enterprise Value

NRIX$2.25B

SLS$2.15B

Price

NRIX$22.35

SLS$11.65

P/E Ratio

NRIXN/A

SLSN/A

P/S Ratio

NRIX63.09x

SLS817.53x

EV/Sales

NRIX61.25x

SLS769.83x

EV/EBITDA

NRIX0.00x

SLS0.00x

P/B Ratio

NRIX5.93x

SLS17.22x

P/FCF Ratio

NRIXN/A

SLSN/A

EV/FCF

NRIX-7.39x

SLS-75.73x

PEG Ratio

NRIXN/A

SLSN/A

Forward P/E (NTM)

NRIXN/A

SLSN/A

Forward P/S (NTM)

NRIX24.84x

SLSN/A

Revenue (TTM)

NRIX$37M

SLS$0

Revenue Growth (YoY)

NRIX-58.4%

SLSN/A

Forward Rev Growth

NRIX66.6%

SLS144.9%

Gross Margin (TTM)

NRIX0.0%

SLS93.1%

Operating Margin (TTM)

NRIX0.0%

SLS0.0%

EBITDA Margin (TTM)

NRIX-959.0%

SLS0.0%

Net Margin (TTM)

NRIX-928.4%

SLS0.0%

FCF Margin (TTM)

NRIX-828.3%

SLSN/A

Net Income (TTM)

NRIX$-341M

SLS$-32M

FCF (TTM)

NRIX$-305M

SLS$-28M

EPS (TTM)

NRIX-$3.07

SLS-$0.17

ROE (TTM)

NRIX-7609.0%

SLS-3591.0%

ROA (TTM)

NRIX-5732.0%

SLS-3334.0%

ROIC (TTM)

NRIX-7609.0%

SLS-3591.0%

Cash

NRIX$68M

SLS$138M

Debt

NRIX$0

SLS$0

Net Cash/Debt

NRIX$68M

SLS$138M

Current Ratio (TTM)

NRIX6.34x

SLS18.83x

Quick Ratio (TTM)

NRIX6.16x

SLS18.29x

Debt/Equity (TTM)

NRIX0.00x

SLS0.00x

Debt/Assets (TTM)

NRIX0.0%

SLS0.0%

Interest Coverage (TTM)

NRIXN/A

SLSN/A

Net Debt/EBITDA (TTM)

NRIX0.00x

SLS0.00x

Beta

NRIX1.78

SLS2.68

52W Performance

NRIX123.9%

SLS503.6%

YTD Performance

NRIX23.8%

SLS167.8%

% from 52W High

NRIX-20.8%

SLS-26.6%

% from 52W Low

NRIX148.3%

SLS738.1%

Asset Turnover (TTM)

NRIX0.06x

SLS0.09x

FCF Yield (TTM)

NRIX-13.1%

SLS-1.2%

Earnings Yield (TTM)

NRIX-14.7%

SLS-1.4%

Dividend Yield (TTM)

NRIXN/A

SLSN/A

Rule of 40

NRIX-886.7

SLS0.0

EV/GP/RG

NRIXN/A

SLSN/A

Ticker research

View NRIX research View SLS research

Metric	NRIX Nurix Therapeutics Inc	SLS Sellas Life Sciences Group Inc
Market & Valuation
Market Cap	$2.32B	$2.29B
Enterprise Value	$2.25B	$2.15B
Price	$22.35	$11.65
P/E Ratio	N/A	N/A
P/S Ratio	63.09x	817.53x
EV/Sales	61.25x	769.83x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.93x	17.22x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.39x	-75.73x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	24.84x	N/A
Revenue & Growth
Revenue (TTM)	$37M	$0
Revenue Growth (YoY)	-58.4%	N/A
Forward Rev Growth	66.6%	144.9%
Profitability
Gross Margin (TTM)	0.0%	93.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-959.0%	0.0%
Net Margin (TTM)	-928.4%	0.0%
FCF Margin (TTM)	-828.3%	N/A
Net Income (TTM)	$-341M	$-32M
FCF (TTM)	$-305M	$-28M
EPS (TTM)	-$3.07	-$0.17
ROE (TTM)	-7609.0%	-3591.0%
ROA (TTM)	-5732.0%	-3334.0%
ROIC (TTM)	-7609.0%	-3591.0%
Financial Health
Cash	$68M	$138M
Debt	$0	$0
Net Cash/Debt	$68M	$138M
Current Ratio (TTM)	6.34x	18.83x
Quick Ratio (TTM)	6.16x	18.29x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.78	2.68
52W Performance	123.9%	503.6%
YTD Performance	23.8%	167.8%
% from 52W High	-20.8%	-26.6%
% from 52W Low	148.3%	738.1%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.09x
FCF Yield (TTM)	-13.1%	-1.2%
Earnings Yield (TTM)	-14.7%	-1.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-886.7	0.0
EV/GP/RG	N/A	N/A
Ticker research	View NRIX research	View SLS research

Valuation

P/S Ratio

NRIX

63.09x

SLS

817.53x

EV/FCF

SLS

-75.73x

NRIX

-7.39x

Growth & revenue

Revenue Growth TTM

NRIX

-58.4%

Forward Revenue Growth

SLS

144.9%

NRIX

66.6%

Profitability & performance

Gross Margin

SLS

93.1%

NRIX

0.0%

ROE

SLS

-3591.0%

NRIX

-7609.0%

FCF Yield %

SLS

-1.2%

NRIX

-13.1%

52-Week Performance

SLS

503.6%

NRIX

123.9%

Detailed metrics comparison

NRIX

Nurix Therapeutics Inc

SLS

Sellas Life Sciences Group Inc

Market Cap

NRIX$2.32B

SLS$2.29B

Enterprise Value

NRIX$2.25B

SLS$2.15B

Price

NRIX$22.35

SLS$11.65

P/E Ratio

NRIXN/A

SLSN/A

P/S Ratio

NRIX63.09x

SLS817.53x

EV/Sales

NRIX61.25x

SLS769.83x

EV/EBITDA

NRIX0.00x

SLS0.00x

P/B Ratio

NRIX5.93x

SLS17.22x

P/FCF Ratio

NRIXN/A

SLSN/A

EV/FCF

NRIX-7.39x

SLS-75.73x

PEG Ratio

NRIXN/A

SLSN/A

Forward P/E (NTM)

NRIXN/A

SLSN/A

Forward P/S (NTM)

NRIX24.84x

SLSN/A

Revenue (TTM)

NRIX$37M

SLS$0

Revenue Growth (YoY)

NRIX-58.4%

SLSN/A

Forward Rev Growth

NRIX66.6%

SLS144.9%

Gross Margin (TTM)

NRIX0.0%

SLS93.1%

Operating Margin (TTM)

NRIX0.0%

SLS0.0%

EBITDA Margin (TTM)

NRIX-959.0%

SLS0.0%

Net Margin (TTM)

NRIX-928.4%

SLS0.0%

FCF Margin (TTM)

NRIX-828.3%

SLSN/A

Net Income (TTM)

NRIX$-341M

SLS$-32M

FCF (TTM)

NRIX$-305M

SLS$-28M

EPS (TTM)

NRIX-$3.07

SLS-$0.17

ROE (TTM)

NRIX-7609.0%

SLS-3591.0%

ROA (TTM)

NRIX-5732.0%

SLS-3334.0%

ROIC (TTM)

NRIX-7609.0%

SLS-3591.0%

Cash

NRIX$68M

SLS$138M

Debt

NRIX$0

SLS$0

Net Cash/Debt

NRIX$68M

SLS$138M

Current Ratio (TTM)

NRIX6.34x

SLS18.83x

Quick Ratio (TTM)

NRIX6.16x

SLS18.29x

Debt/Equity (TTM)

NRIX0.00x

SLS0.00x

Debt/Assets (TTM)

NRIX0.0%

SLS0.0%

Interest Coverage (TTM)

NRIXN/A

SLSN/A

Net Debt/EBITDA (TTM)

NRIX0.00x

SLS0.00x

Beta

NRIX1.78

SLS2.68

52W Performance

NRIX123.9%

SLS503.6%

YTD Performance

NRIX23.8%

SLS167.8%

% from 52W High

NRIX-20.8%

SLS-26.6%

% from 52W Low

NRIX148.3%

SLS738.1%

Asset Turnover (TTM)

NRIX0.06x

SLS0.09x

FCF Yield (TTM)

NRIX-13.1%

SLS-1.2%

Earnings Yield (TTM)

NRIX-14.7%

SLS-1.4%

Dividend Yield (TTM)

NRIXN/A

SLSN/A

Rule of 40

NRIX-886.7

SLS0.0

EV/GP/RG

NRIXN/A

SLSN/A

Ticker research

View NRIX research View SLS research

Metric	NRIX Nurix Therapeutics Inc	SLS Sellas Life Sciences Group Inc
Market & Valuation
Market Cap	$2.32B	$2.29B
Enterprise Value	$2.25B	$2.15B
Price	$22.35	$11.65
P/E Ratio	N/A	N/A
P/S Ratio	63.09x	817.53x
EV/Sales	61.25x	769.83x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.93x	17.22x
P/FCF Ratio	N/A	N/A
EV/FCF	-7.39x	-75.73x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	24.84x	N/A
Revenue & Growth
Revenue (TTM)	$37M	$0
Revenue Growth (YoY)	-58.4%	N/A
Forward Rev Growth	66.6%	144.9%
Profitability
Gross Margin (TTM)	0.0%	93.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-959.0%	0.0%
Net Margin (TTM)	-928.4%	0.0%
FCF Margin (TTM)	-828.3%	N/A
Net Income (TTM)	$-341M	$-32M
FCF (TTM)	$-305M	$-28M
EPS (TTM)	-$3.07	-$0.17
ROE (TTM)	-7609.0%	-3591.0%
ROA (TTM)	-5732.0%	-3334.0%
ROIC (TTM)	-7609.0%	-3591.0%
Financial Health
Cash	$68M	$138M
Debt	$0	$0
Net Cash/Debt	$68M	$138M
Current Ratio (TTM)	6.34x	18.83x
Quick Ratio (TTM)	6.16x	18.29x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.78	2.68
52W Performance	123.9%	503.6%
YTD Performance	23.8%	167.8%
% from 52W High	-20.8%	-26.6%
% from 52W Low	148.3%	738.1%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.09x
FCF Yield (TTM)	-13.1%	-1.2%
Earnings Yield (TTM)	-14.7%	-1.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-886.7	0.0
EV/GP/RG	N/A	N/A
Ticker research	View NRIX research	View SLS research